J&J Wins FDA Nod for First Targeted Oral Anti-IL-23 Therapy for Plaque Psoriasis

By /

Icotyde is backed by data from the Phase 3 ICONIC program which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.

Scroll to Top